SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-162003
Filing Date
2024-06-17
Accepted
2024-06-17 06:31:31
Documents
17
Period of Report
2024-06-13
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d785247d8k.htm   iXBRL 8-K 30611
2 EX-1.1 d785247dex11.htm EX-1.1 300154
3 EX-4.1 d785247dex41.htm EX-4.1 68212
4 EX-5.1 d785247dex51.htm EX-5.1 9511
8 GRAPHIC g785247g0615112718150.jpg GRAPHIC 2179
  Complete submission text file 0001193125-24-162003.txt   638491

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA rare-20240613.xsd EX-101.SCH 2859
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE rare-20240613_lab.xml EX-101.LAB 17235
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rare-20240613_pre.xml EX-101.PRE 10818
20 EXTRACTED XBRL INSTANCE DOCUMENT d785247d8k_htm.xml XML 3494
Mailing Address 60 LEVERONI COURT NOVATO CA 94949
Business Address 60 LEVERONI COURT NOVATO CA 94949 415-483-8800
Ultragenyx Pharmaceutical Inc. (Filer) CIK: 0001515673 (see all company filings)

IRS No.: 272546083 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36276 | Film No.: 241046909
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)